RxDoctor Payments Data

Andrew Bridges

Family · Augusta, GANPI 1174118699

Payments from drug & device makers

$977in general payments, 2019–2025

Across 44 payments — averaging $22.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$178
  • Teleflex LLC$145
  • AbbVie$85
  • Accord Healthcare, Inc.$65
  • Medtronic$49
  • Lilly USA, LLC$48
  • plus $406 from 16 others

What the payments were for

  • Food & beverage$977100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$977 in reported general payments places this provider in the 65th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$3,795
Medicare patients
24
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$71,614
FarxigaDapagliflozin Propanediol16$20,422
JardianceEmpagliflozin16$20,295
EliquisApixaban18$20,044
GemtesaVibegron17$16,880
MyrbetriqMirabegron17$9,451
XareltoRivaroxaban11$7,360
Albuterol Sulfate HfaAlbuterol Sulfate63$1,833
Tamsulosin Hcl75$934
Glipizide18$552
Atorvastatin Calcium69$520
Ezetimibe14$513
Gabapentin46$399
Duloxetine Hcl13$356
Amlodipine Besylate87$252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$71,61449 claims
AstraZenecaFarxiga$45$20,42216 claims
Boehringer IngelheimJardiance$35$20,29516 claims
PfizerEliquis$38$20,04418 claims
Sumitomo Pharma America, Inc.Gemtesa$178$16,88017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,258 family providers in Georgia.

Other family in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →